A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors
暂无分享,去创建一个
B. Schäfer | P. Bode | M. Wachtel | G. Manzella | Devmini Moonamale | Michaela Römmele | Gabriele Manzella | Marco Wachtel